EuropaBio calling for EU Biotech Act
EuropaBio calls for an ambitious cross-sectoral EU Biotech Act, that strengthens Europe as a global biotechnology leader for competitiveness and strategic autonomy.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
PRAC: Semaglutide linked to rare eye disease?
/in News/by Thomas GabrielczykThe Safety Committee PRAC of the European Medicines Agency EMA is investigating a new potential adverse reaction to the appetite suppressant semaglutide. Epidemiological studies indicate that the rare eye disease non-arteritic anterior ischaemic optic neuropathy (NAION), which leads to blindness, could occur more frequently after treatment with the GLP-1 receptor agonist.
InflaRx secures European Commission approval for ARDS drug
/in News/by Thomas GabrielczykJena-based InflaRx has reached a significant milestone with the European Commission’s approval of GOHIBIC (Vilobelimab), a novel anti-C5a monoclonal antibody for the treatment of SARS-CoV-2-induced Acute Respiratory Distress Syndrome (ARDS).
Synairgen raises £18m for Phase 2 INVENT trial of SNG001
/in News/by Thomas GabrielczykSynairgen plc (SNG) has announced the successful completion of a £18m funding round, primarily supported by TFG Asset Management. The funding will advance the Phase 2 INVENT trial, assessing SNG001, an inhaled formulation of the antiviral protein interferon beta, in mechanically ventilated patients with severe viral lung infections.
Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion
/in News/by Thomas GabrielczykJohnson & Johnson has announced the acquisition of biopharmaceutical company Intra-Cellular Therapies, strengthening its position in the market for central nervous system disorder treatments. The $14.6 billion deal involves J&J paying $132 per share, representing a 39% premium over Intra-Cellular’s last closing price.
Leyden Labs secures $70M to advance intranasal antibody therapies
/in News/by Thomas GabrielczykLeyden Labs has raised $70 million in a funding round led by ClavystBio and Polaris Partners, boosting its efforts to develop intranasal antibody therapies targeting respiratory viruses, including influenza and coronaviruses.
First in vivo CAR gene therapy trial in Europe approved
/in News/by Thomas GabrielczykThe Paul Ehrlich Institute (PEI) has approved expansion of the global INVISE Phase 1 clinical trial to Europe. The study aims to evaluate first-in-class gene therapy for the treatment of B-cell malignancies.
Angelini Ventures co-leads €20m Series A to advance RNA therapeutics for neurological disorders
/in News/by Thomas GabrielczykAngelini Ventures, the corporate venture capital arm of Angelini Industries, focused on investing in early-stage companies in BioTech and Digital Health, co-leads €20m Series A funding round in Neumirna Therapeutics, accelerating next-generation RNA therapeutics for epilepsy and neurological diseases.
New RNA company Inverna Therapeutics launched
/in News/by Thomas GabrielczykInverna Therapeutics, a Danish biotech company, has officially launched to develop innovative RNA-based therapies targeting severe genetic diseases. Co-founded by the University of Southern Denmark and Argobio, Inverna will focus on its lead programme addressing Huntington’s disease.
USD410m Mega Series A for yet another GLP-1 play?
/in News/by Thomas GabrielczykVerdiva Bio, a London-based biotech, has raised an extraordinary US$410m in its oversubscribed Series A round, making it potentially the largest Series A ever raised by a U.K.-based biotech company, according to CEO Khurem Farooq.